Loading…
← CockpitCompetitor Analysis › 301584.SZ Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class AOpen in the cockpit ↗

Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. Class A301584.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Distributors

Medical-technology/distribution unit of the Xiamen C&D trading conglomerate; exact product scope not independently confirmed.

Momentum weak 29
Mkt cap
$1.06B
US dollars, full cap
$/day
$13.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+3.9 pp
WACC 5.0%
Hurdle
-21 pp
Req g minus delivered
Close · CNYCN¥17.13
1D-3.2%
1W-13.9%
1M-5.7%
3M-27.5%
6M-33.4%
YTD-41.4%
1Y-51.6%
ATR %4.8%
52w lowhigh57.7% off high

What Shanghai C and D INNOSTIC Medical Technology does

Medical-technology/distribution unit of the Xiamen C&D trading conglomerate; exact product scope not independently confirmed.

Where it sits in the supply chain

  • Health Care
  • Medical distribution

Moat: none

Headquarters: Xiamen, Fujian, China · Employees: 2,115

Shanghai C and D INNOSTIC Medical Technology at a glance

Size Shanghai C and D INNOSTIC Medical Technology (301584.SZ) is a China Health Care company (Medical Distributors) with a market value of $1.06B, the 2049th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.13 on 18 Nov 2026.

Performance Over six months the shares fell 33.4%, against -2.3% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 8.4% over the last twelve months (peer median +5.0%); the operating margin is 3.1% (peer median 2.3%).

Valuation It trades at 0.5× enterprise value to sales against a peer median of 0.8× (9th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -21 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.9 points above its cost of capital (5.0% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 99301584.SZ 67
Six months, rebased to 100: Shanghai C and D INNOSTIC Medical Technology against the median of its 20 peers (local-currency closes).

Shanghai C and D INNOSTIC Medical Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥19.9BCN¥19.4BCN¥17.9BCN¥15.4BCN¥11.9B
Revenue growth—+8%+16%+30%—
Gross profitCN¥1.62BCN¥1.44BCN¥1.25BCN¥1.14BCN¥864M
EBITDAn/aCN¥701MCN¥646MCN¥511MCN¥364M
Net incomeCN¥293MCN¥270MCN¥228MCN¥196MCN¥174M
Free cash flowCN¥909MCN¥668MCN¥43.4M-CN¥457M-CN¥661M
Capital expenditureCN¥72.6MCN¥80.7MCN¥121MCN¥82.4MCN¥33.5M
Total debtCN¥4.67BCN¥4.53Bn/aCN¥3.87BCN¥2.65B

Quarterly statements and history in the cockpit →

Shanghai C and D INNOSTIC Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%0%+20%DOCM7476600587600713603368ARJO-BENTERO68263360NEURDC6006283013709987605136603716008930ASKER301584.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai C and D INNOSTIC Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%0×1×2×DOCM7476600587600713603368ARJO-BENTERO68263360NEURDC81292733600628301370605136603716008930ASKER301584.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai C and D INNOSTIC Medical Technology is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%7476600587603368ENTERO68263360NEU8129600628301370605136008930ASKER301584.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai C and D INNOSTIC Medical Technology is the large dot.

Shanghai C and D INNOSTIC Medical Technology competitors and peer comparison

How Shanghai C and D INNOSTIC Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai C and D INNOSTIC Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure301584.SZPeer medianRank in peer set
1-month return-5.7%-0.1%4th lowest of 21
6-month return-33.4%-2.3%lowest of 21
Distance from 52-week high-57.7%-18.5%lowest of 21
Revenue growth (TTM)+8.4%+5.0%7th highest of 21
Operating margin3.1%2.3%10th highest of 21
EV / Sales0.5×0.8×9th cheapest of 21
Growth the price implies (Req g, 7 yrs)-2.7%-0.5%7th least demanding of 17
Growth delivered (Del g)+17.9%+6.1%2nd highest of 17
Hurdle (Req g minus delivered)-20.6 pp-5.8 pp2nd least demanding of 17
ROIC minus cost of capital+3.9 pp+0.3 pp3rd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%0.5×-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%1.0×n/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%1.3×0.0%+6.3%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%0.6×-6.9%+1.2%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%0.3×n/an/a
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%0.4×-9.7%+6.0%
Arjo ARJO-B.STSweden$974M+42%0%8%1.3×-1.0%+3.9%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%1.2×24.7%+29.9%
Shanghai Haohai Biological Technology 6826.HKHong Kong$897M-24%-5%-2%1.9×17.0%+12.4%
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%0.2×-14.5%+7.6%
Neuca NEU.WAPoland$795M-9%+8%2%0.3×5.3%+8.1%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%0.5×n/an/a
Toho 8129.TJapan$1.64B-5%+4%1%0.1×-4.6%+5.1%
Arata 2733.TJapan$576M-3%+3%1%0.1×-6.2%+3.8%
Shanghai New World 600628.SSChina$573M-10%-2%6%2.1×-1.6%+1.0%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%0.7×13.1%+7.5%
Suzuken 9987.TJapan$2.36B+8%+5%1%0.1×-10.4%+3.2%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%1.1×21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%4.3×n/an/a
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%2.5×26.0%+9.6%
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%1.8×4.7%+12.7%

Questions

Which companies are Shanghai C and D INNOSTIC Medical Technology's closest peers?
The cockpit's peer set: DocMorris (DOCM.SW), AS ONE (7476.T), Shinva Medical Instrument (600587.SS), Nanjing Pharmaceutical (600713.SS), Guangxi LiuYao (603368.SS), Arjo (ARJO-B.ST), Entero Healthcare Solutions (ENTERO.NS), Shanghai Haohai Biological Technology (6826.HK).
Is Shanghai C and D INNOSTIC Medical Technology expensive compared with its peers?
On ev / sales it trades at 0.5× against a peer median of 0.8×, 9th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -21 pp: the price already allows for a slowdown.
How has Shanghai C and D INNOSTIC Medical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -33.4% against -2.3% for the median peer; over one year -51.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.